“Real-world outcomes with Nidra® TOMAC for refractory RLS: integrating THRIVE registry data with prescriber perspectives.”
Thursday, April 16, 2026 at 12:00pm-1:00pm ET
Overview:
Millions of adults with restless legs syndrome (RLS) are becoming refractory to medication, largely due to augmentation to dopamine agonists. The groundbreaking 2025 AASM guidelines for restless legs syndrome (RLS) recommend against dopamine agonists and suggest alternative treatment options including high-frequency peroneal nerve stimulation. The Nidra® tonic motor activation (TOMAC) system is the only commercially available device that delivers high-frequency peroneal nerve stimulation.
Here, we review real-world outcomes for patients prescribed Nidra® TOMAC as part of standard of care in the United States between 2024 and 2025. Dr. Jonathan Charlesworth presents interim clinical outcomes data from the THRIVE real-world registry demonstrating the long-term safety and effectiveness of TOMAC. Dr. Andrew Spector provides his clinical experience as a sleep neurologist who has prescribed TOMAC to dozens of his patients.
Learning Objectives:
Review the burden of refractory RLS and the prevalence of augmentation.
Describe the benefits and risks of TOMAC.
Identify where TOMAC fits in the continuum of care for RLS.
Describe the typical prescriber experience with TOMAC.
Speakers:
Jonathan Charlesworth, PhD – Chief Scientific Officer & Co-Founder at Noctrix Health
Andrew Spector, MD – Professor of Neurology, Duke University School of Medicine
The SRS and the SRSF do not endorse any products discussed in this session.
Complimentary, Advanced Registration is Required.
